Sheppard Mullin advised Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS), a U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, including COVID-19, with its underwritten follow-on public offering of American Depositary Shares on the NASDAQ Global Market, raising approximately $10 million.
Partner Jeffrey Fessler and associate Justin Anslow represented Tiziana Life Sciences in the public offering.
Click here to read the press release.